What investment strategy does 4Bio Partners focus on?

4Bio Partners focuses on VC strategies in the private equity space.

How many portfolio companies does 4Bio Partners have?

4Bio Partners has 14 active portfolio companies and 3 completed exits and 2 funds tracked on GP Intel.

Where is 4Bio Partners headquartered?

4Bio Partners is headquartered in London, United Kingdom.

When was 4Bio Partners founded?

4Bio Partners was founded in 2018.

What sectors does 4Bio Partners invest in?

4Bio Partners invests across Healthcare.

What are 4Bio Partners's recent exits?

Recent realized exits by 4Bio Partners include: Araris Biotech (2025) to Taiho Pharmaceutical; Redpin Therapeutics (2022) to Kriya Therapeutics.

Home/GPs/4Bio Partners

DetailCard

4Bio Partners

London, United Kingdom·Founded 2018·

Venture Capital

·4biocapital.com

4Bio Partners, which trades as 4BIO Capital, is a London-headquartered venture capital firm that invests exclusively in the advanced-therapies sector. It backs early-stage life-science companies developing cell and gene therapies, RNA-based therapies, targeted therapies, radiopharmaceuticals and microbiome treatments addressing areas of high unmet medical and social need. The wider 4BIO Capital business has invested since 2014, while the UK management entity, 4BIO Partners LLP, was incorporated in October 2018. The firm has invested in more than 25 advanced-therapies companies, with notable outcomes including the public listings of UniQure and Autolus and the trade sales of Orchard Therapeutics and Araris Biotech. It is authorised and regulated by the UK Financial Conduct Authority under firm reference number 842764. Its latest flagship fund, 4BIO Ventures III, is a 2022-vintage vehicle targeting up to USD 200 million.

AUM

–

Funds

vintages 2019–2022

Portfolio

Exits

4Bio Partners is a London venture capital firm with 14 active companies and 3 exits.

SectorsHealthcare

Key takeaways

·Average hold across 3 realized deals: 3 years.
·Top sector focus: Biotech (100% of portfolio).
·Fund cadence: ~3Y between vintages · last raise 2022.

Geography breakdown

7 geographies

6 · 35%

5 · 29%

Switzerland

2 · 12%

Italy

1 · 6%

United States

1 · 6%

Japan

1 · 6%

France

1 · 6%

Key facts

HQLondon, United Kingdom

Founded2018

Website4biocapital.com

Recent exits

4Bio Partners sold Araris Biotech to Taiho Pharmaceutical in 2025 after 5 years.

4Bio Partners sold Redpin Therapeutics to Kriya Therapeutics in 2022 after 2 years.

4Bio Partners took Orchard Therapeutics public in 2018 after 1 year.

Coverage notes

2 funds tracked, 17 portfolio companies (14 active · 3 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund 4Bio Partners has raised, with its portfolio companies. Hand-checked from public filings.

2 funds

Fund

Strategy

Vintage

Size

Assets

Exits

4BIO Ventures III

Life Sciences VC2022€184M14 assets1 exits

Life Sciences VC

2022 · 4yr

€184M

Unrealized

14 held

Company	Entry
Actithera Biotech · Switzerland	2025
Aptadir Therapeutics Biotech · Italy	2026
Ascend Advanced Therapies Biotech · UK	2023
Cloverleaf Bio Biotech · United States	2026
Code Biotherapeutics Biotech · US	2022
Cytospire Therapeutics Biotech · UK	2026
Entact Bio Biotech · US	2022
Hornet Therapeutics Biotech · UK	2024
LUCA Science Biotech · Japan	2022
March Biosciences Biotech · US	2024
Ray Therapeutics Biotech · US	2021
SparingVision Biotech · France	2020
Trogenix Biotech · UK	2023
ViaNautis Bio Biotech · UK	2023

Realized

1 exit

Company	Entry	Exit	Type	Buyer	MOIC
Orchard Therapeutics Biotech · UK	2017	2018	IPO	–	–

4BIO Ventures IIRealising

Life Sciences VC2019€45M0 assets2 exits

Life Sciences VC

2019 · 7yr

€45M

Realized

2 exits

Company	Entry	Exit	Type	Buyer	MOIC
Araris Biotech Biotech · Switzerland	2020	2025	Trade Sale	Taiho Pharmaceutical	–
Redpin Therapeutics Biotech · US	2020	2022	Trade Sale	Kriya Therapeutics	–

About 4Bio Partners

4BIO Partners (4BIO Capital) is one of the few venture capital firms investing exclusively in advanced therapies with approximately $300 million plus of assets under management as of December 2024 across Ventures II and Ventures III (Ventures III is 2023 vintage, with the Development Bank of Japan joining Ventures III in January 2024), headquartered in London. The firm was founded in 2015 as a specialist VC focused on advanced therapies and operates as 4BIO Partners LLP, FCA-regulated.

Investment thesis

4BIO Partners deploys capital through approximately three funds (4BIO Ventures I, II, III), targeting early-stage venture capital exclusively in advanced therapeutics addressing high unmet medical need. Sector focus spans cell and gene therapy, RNA-based therapeutics, targeted therapies, microbiome and broader advanced and emerging biotech modalities. Geographic deployment is global across the US, UK and Europe, London-based. The platform aims to take advanced therapy modalities (cell, gene, RNA) mainstream.

Recent activity

Recent realised exits include an antibody-drug conjugate and biotech acquisition (2024). Recent investments include oncology viral immunotherapy Series A (2025), gene therapy Series A (2024-2025) and radiopharmaceutical and targeted therapy Series A (2024-2025). The platform continues active deployment of Ventures III across the advanced therapeutics mandate.

Frequently asked questions

What investment strategy does 4Bio Partners focus on?: 4Bio Partners focuses on VC strategies in the private equity space.
How many portfolio companies does 4Bio Partners have?: 4Bio Partners has 14 active portfolio companies and 3 completed exits and 2 funds tracked on GP Intel.
Where is 4Bio Partners headquartered?: 4Bio Partners is headquartered in London, United Kingdom.
When was 4Bio Partners founded?: 4Bio Partners was founded in 2018.
What sectors does 4Bio Partners invest in?: 4Bio Partners invests across Healthcare.
What are 4Bio Partners's recent exits?: Recent realized exits by 4Bio Partners include: Araris Biotech (2025) to Taiho Pharmaceutical; Redpin Therapeutics (2022) to Kriya Therapeutics.